[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.62.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 5, 1965

Cyclophosphamide-Prednisone Therapy of Lethal Midline Granuloma

Author Affiliations

From the Department of Medicine and the Chemotherapy Clinic of the Mount Sinai Hospital, New York.

JAMA. 1965;193(1):74-76. doi:10.1001/jama.1965.03090010080031
Abstract

LETHAL MALIGNANT midline granuloma is a relentless, destructive disorder of the facial tissues and other structures. It usually takes a progressive downhill course, lasting one to three years after the onset.1 Less than 150 cases of this rare disease of unknown etiology have been reported since McBride's first description2 in 1897. A close relationship has been postulated between lethal midline granuloma and Wegener's granulomatosis,3 which are both considered to be variants of periarteritis nodosa or other collagen-vascular diseases. A substantial number of patients with midline granuloma experience involvement of the lungs and other distant sites. Such involvements culminate in a terminal clinical state similar to that produced by progressive Wegener's granulomatosis.

Therapy of midline granuloma has been unsatisfactory despite transient response to steroids and temporary healing of individual lesions after x-radiation therapy.4 Long-term regression of progressive midline lethal granuloma by any systemic therapy has not yet

First Page Preview View Large
First page PDF preview
First page PDF preview
×